Q3 2026 Twist Bioscience Corp Earnings Call Transcript

Aug 3, 2026 / 12:00 PM GMT

Release Date Price: €85.6 (+12.78%)

Transcript 10-Q8-K

Key Points

Positve

Record revenue of $118.4 million, up 23% year-over-year, marking the 14th consecutive quarter of growth.
AI-enabled drug discovery orders are expected to meet or exceed triple-digit growth in fiscal 2026, with similar growth anticipated in fiscal 2027.
Gross margin improved to 52.8%, with 70% of incremental revenue flowing to the gross margin line.
Therapeutics revenue surged 49% year-over-year, driven by AI-enabled drug discovery and strong pharma demand.
Complex genes offering launched broadly after successful early access, with over 1,800 constructs delivered on time.
Manufacturing costs reduced by 60% and turnaround time cut by 73% over the last three years, enhancing competitive advantage.
NGS Applications revenue grew 12% year-over-year, with strong growth from top accounts and new product adoption.
Company raised fiscal 2026 revenue guidance to $456-$457 million, reflecting confidence in continued momentum.
Adjusted EBITDA breakeven expected in Q4 fiscal 2026, with a commitment to maintain positive EBITDA in fiscal 2027.
Academic and government revenue grew 32% year-over-year, showing resilience and broad-based demand.

Negative

Adjusted EBITDA loss of $11.3 million in Q3, impacted by one-time employee transition costs and investments.
Operating expenses increased to $98.7 million, up from $81.4 million year-over-year, pressuring profitability.
DNA Synthesis and Protein Solutions revenue growth of 39% was below gene shipment growth of 56%, indicating potential pricing or mix shifts.
Therapeutics revenue declined sequentially, despite strong year-over-year growth, due to order timing and mix.
Global supply partner revenue remained flat at $12.9 million, showing limited growth in this segment.
Industry and applied revenue declined to $5.7 million from $6.1 million year-over-year, indicating softness in this area.
Cash and short-term investments decreased to $166.8 million from $171.7 million, reflecting ongoing cash burn.
Competitive pressures from vendors like Genscript and Turbochill were noted, though management downplayed the impact.
The company's reliance on AI-enabled drug discovery for growth introduces concentration risk if customer demand fluctuates.
Fiscal 2027 guidance is not yet provided, creating uncertainty about long-term growth sustainability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TWST.OQ - Twist Bioscience Corp
Q3 2026 Twist Bioscience Corp Earnings Call
Aug 03, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to TWIST Biosciences 2026 Third Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode.

After the speaker's presentation, there'll be a question-and-answer session. To ask a question, you will need to press *11 on your touchtone telephone. Please note this call is being recorded.

I would like to turn the call over to Angela Bidding, SVP of Corporate Affairs. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good morning, everyone. I'd like to thank you for joining us for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.